Rimegepant

What it is and how it works

Mechanism of Action Rimegepant is a calcitonin gene-related peptide receptor antagonist.

Indications

is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults • preventive treatment of episodic migraine in adults Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.

Dosage and administration (summary)

• Recommended dosage for acute treatment of migraine: 75 mg taken orally, as needed. • The safety of using more than 18 doses in a 30-day period has not been established. • Recommended dosage for preventive treatment of episodic migraine: 75 mg taken orally every other day. • The maximum dose in a 24-hour period is 75 mg. • NURTEC ODT can be taken with or without food. ( 2.1 , 2.2 ) Recommended Dosing for Acute Treatment of Migraine The recommended dose of NURTEC ODT is 75 mg taken orally, as needed. The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established. NURTEC ODT can be taken with or without food .

Contraindications

is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components. Reactions have included anaphylaxis and delayed serious hypersensitivity . Patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or to any of its components.

Warnings and precautions

• Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis, dyspnea, and rash, and can occur days after administration. • Hypertension: New-onset or worsening of pre-existing hypertension may occur. • Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur. Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, dyspnea , and rash, have occurred in patients treated with NURTEC ODT .

Pregnancy

Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to NURTEC ODT during pregnancy. For more information, healthcare providers or patients are encouraged to contact: 1-877-366-0324, email crgnurtecpregnancyregistry@thermofisher.com, or visit nurtecpregnancyregistry.com .

Storage and supply

Storage and Handling Store NURTEC ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F); with excursions permitted between 15°C to 30°C (59°F to 86°F) .

Source: Rimegepant Sulfate (Nurtec Odt) — US FDA prescribing information, 2026-06-04, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.